Goldman Sachs analyst Chris Shibutani upgraded Pfizer to Buy from Neutral with a price target of $60, up from $47.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer to Expand Its mRNA Vaccine Arsenal
- Pfizer sees $1B-$2B of potential annual revenue from UC drug Etrasimod
- Canada approves Pfizer, BioNTech booster vaccine for children 5 to 12
- Pfizer raises quarterly cash dividend to 41c from 40c per share
- Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate